ReviewThe American journal of psychiatry2010
Medication treatment of different types of alcoholism.
Review in The American journal of psychiatry, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 1 synthesis or guideline pooled it, 148 citations in OpenAlex.
- Pooled it
- Social network moderators of naltrexone and behavioral treatment effects on heavy drinking in the COMBINE study.Alcoholism, clinical and experimental research · 2015Trial
- The effects of binge drinking on healthy and diseased livers.Canadian liver journal · 2021Review
- Design of a randomized controlled trial examining the efficacy of oxytocin to enhance alcohol behavioral couple therapy.Contemporary clinical trials · 2019Article
- Alcohol abuse and disorder of granulopoiesis.Pharmacology & therapeutics · 2019Review
- Applications ofChinese herbal medicines · 2019Article
- Are Some Alcohol Use Disorder Criteria More (or Less) Externalizing than Others? Distinguishing Alcohol Use Symptomatology from General Externalizing Psychopathology.Alcoholism, clinical and experimental research · 2019Article
- Murine Drinking Models in the Development of Pharmacotherapies for Alcoholism: Drinking in the Dark and Two-bottle Choice.Journal of visualized experiments : JoVE · 2019Article
- Lipophagy and Alcohol-Induced Fatty Liver.Frontiers in pharmacology · 2019Review
- Increased Alcohol Seeking in Mice Lacking Gpr88 Involves Dysfunctional Mesocorticolimbic Networks.Biological psychiatry · 2018Article
- Sarcopenia in Alcoholic Liver Disease: Clinical and Molecular Advances.Alcoholism, clinical and experimental research · 2017Review
- Rat animal models for screening medications to treat alcohol use disorders.Neuropharmacology · 2017Review
- Medications development for the treatment of alcohol use disorder: insights into the predictive value of animal and human laboratory models.Addiction biology · 2017Review
- Preclinical development of moxidectin as a novel therapeutic for alcohol use disorder.Neuropharmacology · 2017Article
- Nicotine Increases Alcohol Intake in Adolescent Male Rats.Frontiers in behavioral neuroscience · 2017Article
- Analysis of alcohol use disorders from the Nathan Kline Institute-Rockland Sample: Correlation of brain cortical thickness with neuroticism.Drug and alcohol dependence · 2017Article
- Voluntary wheel running reduces voluntary consumption of ethanol in mice: identification of candidate genes through striatal gene expression profiling.Genes, brain, and behavior · 2016Article
- Multidisciplinary View of Alcohol Use Disorder: From a Psychiatric Illness to a Major Liver Disease.Biomolecules · 2016Review
- A Genetic Animal Model of Alcoholism for Screening Medications to Treat Addiction.International review of neurobiology · 2016Review
- The pharmacogenetics of alcohol use disorder.Alcoholism, clinical and experimental research · 2015Review
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Alcoholism remains a serious cause of morbidity and mortality despite progress through neurobiological research in identifying new pharmacological strategies for its treatment. Drugs that affect neural pathways that modulate the activity of the cortico-mesolimbic dopamine system have been shown to alter drinking behavior, presumably because this dopaminergic system is closely associated with rewarding behavior. Ondansetron, naltrexone, topiramate, and baclofen are examples. Subtyping alcoholism in adults into an early-onset type, with chronic symptoms and a strong biological predisposition to the disease, and a late-onset type, typically brought on by psychosocial triggers and associated with mood symptoms, may help in the selection of optimal therapy. Emerging adults with binge drinking patterns also might be aided by selective treatments. Although preliminary work on the pharmacogenetics of alcoholism and its treatment has been promising, the assignment to treatment still depends on clinical assessment. Brief behavioral interventions that encourage the patient to set goals for a reduction in heavy drinking or abstinence also are part of optimal therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.